Join the Oncology
Community
Follow Us:  

Brachytherapy Doubles Breast Loss Risk

By: BRUCE JANCIN,  Oncology Report Digital Network

SAN ANTONIO – Accelerated partial-breast brachytherapy, delivered as part of breast-conserving therapy for early breast cancer, was associated with twice the mastectomy rate when compared with standard whole-breast irradiation in a large study.

Moreover, accelerated partial-breast brachytherapy entailed substantially higher rates of both acute and late complications, Dr. Benjamin D. Smith said in a presentation of the study findings at the San Antonio Breast Cancer Symposium.

Investigators reviewed Medicare claims data for all 130,535 beneficiaries whose early breast cancer was treated with lumpectomy followed by adjuvant radiation during 2000-2007. The use of accelerated partial-breast brachytherapy in this population rose from less than 1% in 2000 to 13% in 2007.

The incidence of mastectomy during 5 years of follow-up was 4% in 7,291 brachytherapy recipients, compared with 2% after whole breast irradiation (P less than .001). Upon adjustment for the brachytherapy recipients’ older average age, more comorbid conditions, and lesser rate of positive axillary lymph nodes, brachytherapy was associated with a 2.2-fold increased risk of losing the treated breast within 5 years, reported Dr. Smith, a radiation oncologist at the University of Texas M.D. Anderson Cancer Center, Houston.

"When we adjusted for various clinical and sociodemographic factors, to our surprise brachytherapy was the variable that had the strongest correlation with the risk of subsequent mastectomy," he noted.

Partial-breast brachytherapy was also associated with significantly higher rates of postoperative wound infection and acute noninfectious complications as well as increased 5-year rates of fat necrosis and breast pain. Fat necrosis is considered a marker of tissue injury caused by surgery and/or radiotherapy.

Within 1 year of breast cancer diagnosis, infectious complications involving breast or surrounding skin or soft tissues occurred in 16% of women treated with brachytherapy vs. 10% of those who received standard whole breast radiation.

Noninfectious complications including surgical wound breakdown, postoperative bleeding, or seroma formation were twice as common with brachytherapy at 16% and 8%, respectively.

Five-year rates of fat necrosis (9% vs. 4%) and breast pain (15% vs. 12%) also were higher with brachytherapy.

Accelerated partial-breast brachytherapy was developed to address the shortcomings of whole-breast irradiation, the historic standard of care, which entails up to 7 weeks of daily Monday-through-Friday treatment. Whole-breast irradiation is inconvenient. Indeed, it’s such a hardship, especially for patients in rural areas distant from a radiotherapy center, that some women opt for mastectomy as a matter of convenience. Moreover, 15%-30% of women who undergo lumpectomy forgo prescribed radiation therapy, placing themselves at increased risk of local recurrence.

Accelerated partial-breast brachytherapy may improve patient compliance with radiotherapy. It shortens the treatment course to 1 week. It entails temporary placement of radioactive beads within the breast via a catheter system. This method delivers radiation only to breast tissue immediately adjacent to the lumpectomy. This technique is but one of several forms of partial breast irradiation, however; the new findings don’t apply to 3-D external beam radiation, for example.

View on the News

ASTRO Calls Brachytherapy Still 'Suitable' For Selected Patients

The American Society for Radiation Oncology has issued a statement of concern regarding the potential for misinterpretation of the accelerated partial-breast brachytherapy study. Brachytherapy is a faster, more convenient alternative to standard whole-breast irradiation, and brachytherapy technology has improved dramatically since the study years of 2000-2007. Moreover, this was not a randomized trial, and definitive results from ongoing randomized trials comparing the safety and efficacy of brachytherapy and standard whole-breast irradiation are still years off. In the interim, it is appropriate to continue using brachytherapy outside of clinical trials under selected circumstances as described in a 2009 ASTRO consensus statement. The first author of the consensus statement was Dr. Benjamin D. Smith, who presented the brachytherapy findings in San Antonio.

The ASTRO statement (J. Am. Coll. Surg. 2009;209:269-77) was forged by a task force that conducted an extensive literature review. Task force members defined a group suitable for accelerated partial-breast brachytherapy outside of clinical trials based upon the following characteristics: age 60 years or older, no BRCA mutations, tumor size not more than 2 cm, T1, estrogen receptor-positive, unicentric and unifocal, node-negative, no neoadjuvant therapy, no extensive intraductal component of the breast cancer, and no pure ductal carcinoma in situ. The consensus statement also defines other patient groups for whom caution must be applied when considering brachytherapy outside of a clinical trial, as well as a group for whom such therapy is unacceptable.

The new brachytherapy study should provide an additional incentive for physicians to be cautious in choosing which patients to recommend for accelerated partial-breast irradiation. For the time being, physicians should continue to encourage enrollment in trials and adhere to a conservative approach to accelerated partial-breast brachytherapy as indicated in the ASTRO consensus panel statement.

Dr. Bruce Haffty, a coauthor of the consensus statement, is professor and chairman of radiation oncology at the Robert Wood Johnson Medical School in New Brunswick, N.J.

12/07/11  

FROM THE SAN ANTONIO BREAST CANCER SYMPOSIUM

Bookmark and Share


Submitting your vote...
Average rating: 5.0 of 5
Click the rating bar to rate this item.

Vitals

Major Finding: Accelerated partial-breast brachytherapy had a twofold higher 5-year mastectomy rate than whole breast irradiation and substantially higher complication rates as well.

Data Source: An observational study of claims data for all of the more than 130,000 Medicare patients who underwent lumpectomy with adjuvant radiation in 2000-2007.

Disclosures: No financial conflicts were reported.

View on the News

ASTRO Calls Brachytherapy Still 'Suitable' For Selected Patients

Current Issue


The Oncology Report Comprehensive reports and expert commentary on the latest advances in cancer treatment from the world's major oncology meetings.

Past issues, click here »


calendar


Dr. Benjamin D.Smith

Jun 1 - 5
Chicago, IL
American Society of Clinical Oncology (ASCO): Annual Meeting
Jun 14 - 17
Amsterdam,
European Hematology Association (EHA): Annual Congress
Jun 18 - 21
Lake Tahoe, NV
American Association for Cancer Research (AACR): Pancreatic Cancer: Progress and Challenges
Jun 20 - 22
Milan,
European Institute of Oncology (IEO): 14th Milan Breast Cancer Conference
Jun 25 - 26
London,
Teenage Cancer Trust (TCT): International Conference
Jun 27 - 30
Barcelona,
European Society for Medical Oncology (ESMO) Conference: World Congress on Gastrointestinal Cancer
Jun 27 - 30
Boston, MA
American Association for Cancer Research (AACR): Chemical Systems Biology
Jun 28 - 30
New York, NY
Multinational Association of Supportive Care in Cancer (MASCC)/ International Society of Oral Oncology (ISOO): International Symposium
Jun 28 - 29
Paris,
WIN 2012 Symposium
Jul 7 - 10
Barcelona,
22nd Biennial Congress of the European Association for Cancer Research
More Calendar »